The risk associated with aprotinin in cardiac surgery.
Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation
N Engl J Med 2006;354(4):353-365.
Review by
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM
JAMA 2006;295(3):293-298.
Review by M. Aldouri
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Aledort LM
J Thromb Haemost 2004;2(10):1700-1708.
Review by
Recombinant factor VIIa: how safe is the stuff?
Roberts HR
Can J Anaesth 2005;52(1):8-11.
Review by
Transfusion medicine service policies for recombinant factor VIIa administration.
Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C
Transfusion 2004;44(9):1325-1331.
Review by M. Aldouri
Preoperative acute normovolemic hemodilution: a meta-analysis.
Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E
Transfusion 2004;44(5):632-644.
Review by
Patient safety and blood transfusion: new solutions.
Dzik WH, Corwin H, Goodnough LT, et al.
Transfus Med Rev 2003;17(3):169-180.
Review by
Transfusion risks of yesterday and of today. [Article in French]
Allain JP
Transfus Clin Biol 2003;10(1):1-5.
Review by
Tolerance to acute isovolemic hemodilution: effect of anesthetic depth.
Van Der Linden P, De Hert S, Mathieu N
Anesthesiology 2003;99(1):97-104.
Review by
Experience with use of recombinant activated factor VII.
Divanon F, Hecquard C, Borel-Derlon A
J Clin Pharm Ther 2002;27(2):133-138.
Review by
The use of bovine hemoglobin glutamer-250 (Hemopure (R)) in surgical patients: Results of a multicenter, randomized, single-blinded trial.
Sprung J, Kindscher JD, Wahr JA, et al.
Anesth Analg 2002;94(4):799-808.
Review by Hardy JF
Effectiveness of combined blood conservation measures in thoracic aortic operations with deep hypothermic circulatory arrest.
Shibata K, Takamoto S, Kotsuka Y, Sato H
Ann Thorac Surg 2002;73(3):739-743.
Review by Regan F
Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s.
Weinberg PD, Hounshell J, Sherman LA, et al.
Ann Intern Med 2002;19;136(4):312-319.
Review by
Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A.
Lisman T, Mosnier LO, Lambert T, et al.
Blood 2002;99(1):175-179.
Review by
A double-blind study to evaluate the safety of recombinant human hemoglobin in surgical patients during general anesthesia.
Hayes JK, Stanley TH, Lind GH, East K, Smith B, Kessler K
J Cardiothorac Vasc Anesth 2001;15(5):593-602.
Review by Ph. Van der Linden
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659